返回ChemicalBook首页>CAS数据库列表>143201-11-0

143201-11-0

中文名称 西立伐他汀钠
英文名称 Cerivastatin sodium
CAS 143201-11-0
分子式 C26H34FNO5
MDL 编号 MFCD00865716
分子量 459.55
MOL 文件 143201-11-0.mol
143201-11-0 结构式 143201-11-0 结构式

基本信息

中文别名
西立伐他汀钠
(+)-(3R,5S,6E)-7-[4-(4-氟苯基)-2,6-二异丙基-5-甲氧甲基-吡啶-3-基]-3,5-二羟基-6-庚烯酸单钠盐
英文别名
BAYCOL
CERIVASTATIN
Rivastatin, Baycol, Lipobay
6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-
6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, [S-[R*,S*-(E)]]-
BAY-w 6228
Cerivastatin sodium
Sodium 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyrid in-3-yl]-3,5-dihydroxy-hept-6-enoate
所属类别
原料药:调节血脂药

物理化学性质

熔点197-199°C
比旋光度D20 +24.1° (c = 1 in ethanol)
储存条件Hygroscopic, Store under Inert atmosphere -20°C Freezer
溶解度H2O:≥5mg/mL
形态粉末
颜色白色至棕褐色
旋光性 (optical activity)[α]/D +18 to +26° in ethanol
稳定性吸湿性

安全数据

WGK Germany3

常见问题列表

生物活性
Cerivastatin sodium 是一种合成的降脂剂,是一种高效,耐受性好,口服活性的 HMG-CoA 还原酶抑制剂,Ki 为 1.3 nM/L。Cerivastatin sodium 可降低低密度脂蛋白胆固醇水平。Cerivastatin sodium 还主要通过 RhoA 抑制作用来抑制 MDA-MB-231 细胞的增殖和侵袭,具有抗癌作用。
靶点

Ki: 1.3 nM/L (HMG-CoA reductase)

体外研究

Cerivastatin (5-50 ng/mL; 3 days; MDA-MB-231 cells) treatment induces a dose-dependent decrease in cell proliferation of MDA-MB-231 cells (up to 40% inhibition at 25 ng/mL).
Cerivastatin (25 ng/mL; 18-36 hours; MDA-MB-231 cells) treatment induces an arrest of the cell cycle in G 1/S phase after 36 h treatment. This arrest is not observed for a shorter incubation time (18 h).
Cerivastatin (25 ng/mL; 18 hours; MDA-MB-231 cells) treatment induces a marked increase in the level of p21 Waf1/Cip1 .
Cerivastatin (25 ng/mL; 12 hours; MDA-MB-231 cells) treatment increases the p21 transcript in MDA-MB-231 cells.
Cerivastatin (10-25 ng/mL; 18 hours) inhibits invasion of MDA-MB-231 cells through Matrigel.
Cerivastatin (25 ng/mL; 18-36 hours) delocalizes RhoA and Ras from the membrane to the cytosol and induces morphological changes.
Cerivastatin (25 ng/mL; 4-36 hours) induces inactivation of NFκB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, and concomitantly increases IκB.

Cell Proliferation Assay

Cell Line: MDA-MB-231 cells
Concentration: 5 ng/mL, 10 ng/mL, 25 ng/mL, 50 ng/mL
Incubation Time: 3 days
Result: Induced a dose-dependent decrease in cell proliferation of MDA-MB-231 cells.

Cell Cycle Analysis

Cell Line: MDA-MB-231 cells
Concentration: 25 ng/mL
Incubation Time: 18 hours, 36 hours
Result: Induced a cell cycle block in G 1/S phase.

Western Blot Analysis

Cell Line: MDA-MB-231 cells
Concentration: 25 ng/mL
Incubation Time: 18 hours
Result: Induced a marked increase in the level of p21 Waf1/Cip1 .

RT-PCR

Cell Line: MDA-MB-231 cells
Concentration: 25 ng/mL
Incubation Time: 12 hours
Result: Increased p21 Waf1/Cip1 mRNA levels.
体内研究

Cerivastatin is well absorbed, reaching maximal plasma levels in 1-3 hours following oral dosing. In the circulation, Cerivastatin is highly bound to plasma proteins (99.5%), with an elimination half-life of 2-4 hours. Cerivastatin is metabolized predominantly in the liver to three polar metabolites. Two of these metabolites are active, but to a lesser extent compared to parent drug, and the third metabolite is inactive. Plasma concentrations of all metabolites are substantially lower than those of the parent drug. Elimination of metabolites is via the urine (20-25%) and feces (66-73%), while essentially no parent compound is excreted.

"143201-11-0" 相关产品信息
532-32-1 1310-73-2 15307-79-6 7757-82-6 127-09-3 14639-25-9 108-89-4 7758-19-2 7647-14-5 93957-55-2 79902-63-9 81131-70-6 144-55-8 68-04-2 134523-00-5 599-79-1 51-52-5 140-76-1